An2 Therapeutics, Inc. (ANTX)
$2.4
+0.03
(+1.27%)▲
Live
Insights on An2 Therapeutics, Inc.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 123.1%
Performance
- $2.39$2.44$2.40
0.42%
Downside
Day's Volatility :2.05%
Upside
1.64%
- $2.31$22.22$2.40
3.75%
Downside
52 Weeks Volatility :89.6%
Upside
89.2%
Returns
| Period | An2 Therapeutics, Inc. | Index (Russel 2000) |
|---|---|---|
3 Months | -87.8% | 0.0% |
6 Months | -83.78% | 0.0% |
1 Year | -72.15% | -1.1% |
3 Years | -84.61% | -22.1% |
Highlights
Market Capitalization | 70.3M |
Book Value | $4.19 |
Earnings Per Share (EPS) | -2.74 |
Wall Street Target Price | 16.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -36.07% |
Return On Equity TTM | -58.83% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -2.74 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.57 |
EPS Estimate Next Year | -2.45 |
EPS Estimate Current Quarter | -0.75 |
EPS Estimate Next Quarter | -0.76 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 566.67%
Technicals Summary
Sell
Neutral
Buy
An2 Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 An2 Therapeutics, Inc. | -26.17% | -83.78% | -72.15% | -84.61% | -84.61% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
An2 Therapeutics, Inc. | NA | NA | NA | -2.57 | -0.59 | -0.36 | NA | 4.19 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
An2 Therapeutics, Inc. | Buy | $70.3M | -84.61% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Institutional Holdings
RA Capital Management, LLC
18.67%TCG Crossover Management, LLC
9.01%Bvf Inc
5.26%Citadel Advisors Llc
5.23%HHG PLC
4.30%Avidity Partners Management LP
3.83%
Company Information
an2 therapeutics, inc. is a california-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. an2 is a mission-driven company, with a vision for humanity to be free from the threat of infectious diseases by addressing the urgent need for new treatments that can save lives across the globe. founded by a small team of biopharmaceutical industry leaders with a passion for global health and experience in infectious disease drug r&d, we strive to bring patients treatments that will restore their health and enable them to live productive lives.
Organization | An2 Therapeutics, Inc. |
Employees | 41 |
CEO | Mr. Joseph S. Zakrzewski |
Industry | Services |
